The 10-year cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes mellitus: an intent-to-treat analysis of diabetes prevention

被引：0
|
作者：
Herman, W. [1 ,2 ]
Edelstein, S. [1 ]
Ratner, R. [3 ]
Montez, M. [4 ]
Ackermann, R. [5 ]
Orchard, T. [6 ]
Foulkes, M. [1 ]
Zhang, P. [7 ]
Saudek, C. [8 ]
Brown, M.
机构：
[1] George Washington Univ, Ctr Biostat, Rockville, MD USA
[2] Univ Michigan, Med Ctr, Ann Arbor, MI USA
[3] Medstar Hlth Res Inst, Washington, DC USA
[4] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
[5] Indiana Univ Sch Med, Indianapolis, IN USA
[6] Univ Pittsburgh, Pittsburgh, PA USA
[7] Ctr Dis Control, Atlanta, GA 30333 USA
[8] Johns Hopkins Univ, Baltimore, MD USA
来源：
DIABETOLOGIA | 2011年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
904
引用
收藏
页码：S370 / S370
页数：1
相关论文
共 50 条
  • [41] A comment on "Metformin in the Diabetes Prevention Program 3-year trial: The cost-effectiveness that never was"
    Herman, William H.
    Kuo, Shihchen
    Zhang, Ping
    DIABETES OBESITY & METABOLISM, 2025, 27 (03): : 1626 - 1627
  • [42] Cost-Effectiveness of Structured Lifestyle Programs for Diabetes Prevention in the Medicaid Population
    Laxy, Michael
    Zhang, Ping
    Shao, Hui
    Ng, Boon Peng
    Ali, Mohammed K.
    Gregg, Edward W.
    DIABETES, 2018, 67
  • [43] Cost and cost-effectiveness of mHealth interventions for the prevention and control of type 2 diabetes mellitus: a protocol for a systematic review
    Rinaldi, Giulia
    Hijazi, Alexa
    Haghparast-Bidgoli, Hassan
    BMJ OPEN, 2019, 9 (04):
  • [44] COST-EFFECTIVENESS OF STATINS FOR PRIMARY PREVENTION IN NEWLY DIAGNOSED TYPE 2 DIABETES PATIENTS IN THE NETHERLANDS
    de Vries, F. M.
    Denig, P.
    Visser, S. T.
    Hak, E.
    Postma, M. J.
    VALUE IN HEALTH, 2013, 16 (07) : A526 - A526
  • [45] Cost-Effectiveness of Statins for Primary Prevention in Patients Newly Diagnosed with Type 2 Diabetes in The Netherlands
    de Vries, Folgerdiena M.
    Denig, Petra
    Visser, Sipke T.
    Hak, Eelko
    Postma, Maarten J.
    VALUE IN HEALTH, 2014, 17 (02) : 223 - 230
  • [46] Commentary: Beyond 10-year risk: A cost-effectiveness analysis of statins for the primary prevention of cardiovascular disease
    Shah, Aditya
    Sharma, Kamal
    Rawal, Shalin
    Sisodia, Rhea
    Bhatt, Parjanya
    Christian, Cleris
    Konat, Ashwati
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [47] Cost-effectiveness analysis of aspirin for primary prevention of cardiovascular events among patients with type 2 diabetes in China
    Jiang, Minghuan
    Li, Pengchao
    You, Joyce Hoi-sze
    Zheng, Xinglong
    Deng, Jizhao
    Zhao, Mingyue
    Feng, Liuxin
    Fang, Yu
    PLOS ONE, 2019, 14 (12):
  • [48] Effectiveness of Lifestyle Intervention in Prevention of Type 2 Diabetes in India: A Cluster Randomised Controlled Trial of the Kerala Diabetes Prevention Program
    Sathish, Thirunavukkarasu
    Oldenburg, Brian
    Lotfalian, Mojtaba
    Thankappan, Kavumpurathu R.
    DIABETES, 2017, 66 : A458 - A458
  • [49] Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program
    Herman, WH
    Brandle, M
    Zhang, P
    Williamson, DF
    Matulik, MJ
    Ratner, RE
    Lachin, JM
    Engelgau, MM
    DIABETES CARE, 2003, 26 (01) : 36 - 47
  • [50] Reduction in the incidence of type 2 diabetes mellitus with lifestyle intervention or metformin
    Enzo Bonora
    L’Endocrinologo, 2002, 3 (1) : 91 - 92
12345